These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1966885)

  • 1. Clinical and laboratory precautions that reduce the adverse reactions, alloimmunization, infectivity, and possibly immunomodulation associated with homologous transfusions.
    Wenz B
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):3-7. PubMed ID: 1966885
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection.
    Rawal BD; Davis RE; Busch MP; Vyas GN
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639
    [No Abstract]   [Full Text] [Related]  

  • 3. Canadian Red Cross Society symposium on leukodepletion: report of proceedings.
    Freedman JJ; Blajchman MA; McCombie N
    Transfus Med Rev; 1994 Jan; 8(1):1-14. PubMed ID: 7907899
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components.
    Dzieczkowski JS; Barrett BB; Nester D; Campbell M; Cook J; Sugrue M; Andersen JW; Anderson KC
    Transfusion; 1995 Jan; 35(1):20-5. PubMed ID: 7998063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].
    Handa M; Ikeda Y; Kurata Y; Tsubaki K; Horiuchi A; Furihata K; Kimura Y; Toyama K; Takamoto S; Tsukimoto I
    Rinsho Ketsueki; 1992 Apr; 33(4):451-60. PubMed ID: 1602608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte reduction in blood component therapy.
    Lane TA; Anderson KC; Goodnough LT; Kurtz S; Moroff G; Pisciotto PT; Sayers M; Silberstein LE
    Ann Intern Med; 1992 Jul; 117(2):151-62. PubMed ID: 1605430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients.
    Hume HA; Preiksaitis JB
    Transfus Sci; 1999 Aug; 21(1):73-95. PubMed ID: 10724787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of leucoreduction of blood transfusions.
    Bilgin YM; van de Watering LM; Brand A
    Neth J Med; 2011 Oct; 69(10):441-50. PubMed ID: 22058263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion-associated noncardiogenic pulmonary edema.
    Herman JH; Kamel H
    Transfusion; 1987; 27(3):293. PubMed ID: 3590296
    [No Abstract]   [Full Text] [Related]  

  • 12. Universal leukocyte reduction: Is it appropriate medical practice or not?
    Angelbeck JH; Ortolano GA
    J Infus Nurs; 2005; 28(4):273-81. PubMed ID: 16106211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA antigens on leukocyte fragments and plasma proteins: prestorage leukoreduction by filtration.
    Dzik S; Szuflad P; Eaves S
    Vox Sang; 1994; 66(2):104-11. PubMed ID: 8184591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal WBC reduction: the case for and against.
    Vamvakas EC; Blajchman MA
    Transfusion; 2001 May; 41(5):691-712. PubMed ID: 11346708
    [No Abstract]   [Full Text] [Related]  

  • 16. [Leukocyte depletion of blood products. Indications and technical implementation].
    Böck M; Heim MU
    Fortschr Med; 1995 Mar; 113(8):102-4. PubMed ID: 7759031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of transfusions caused by leukocytes.
    Raife TJ
    J Intraven Nurs; 1997; 20(5):238-44. PubMed ID: 9369624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory failure secondary to homologous blood transfusion.
    Ebert JP; Grimes B; Niemann KM
    Anesthesiology; 1985 Jul; 63(1):104-6. PubMed ID: 3893224
    [No Abstract]   [Full Text] [Related]  

  • 19. Indications for the use of cytomegalovirus-seronegative blood products.
    Preiksaitis JK
    Transfus Med Rev; 1991 Jan; 5(1):1-17. PubMed ID: 1666324
    [No Abstract]   [Full Text] [Related]  

  • 20. Lymphocyte contamination in leukocyte-depleted red cell and platelet concentrates obtained by filtration.
    Müller N; Gummelt M; Osskop S; Schlake C
    Haematol Blood Transfus; 1990; 33():563-5. PubMed ID: 2323656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.